| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -63,093 | -41,565 |
| Depreciation and amortization | 1,931 | 1,269 |
| Stock-based compensation | 5,232 | 3,601 |
| Accretion of discounts and amortization of premiums on investments, net | 1,589 | 1,232 |
| Other receivables (including related party amounts of (37) and (593), respectively) | -67 | -116 |
| Prepaid expenses and other current assets | 3,420 | 3,614 |
| Other long-term assets | 151 | -229 |
| Accounts payable (including related party amounts of (276) and 104, respectively) | -610 | -168 |
| Accrued expenses (including related party amounts of (702) and (854), respectively) | -362 | -1,481 |
| Operating lease right-of-use asset and lease liabilities, net | -30 | 21 |
| Net cash used in operating activities | -62,025 | -42,824 |
| Purchases of property and equipment | 2,166 | 1,566 |
| Purchases of investments | 37,336 | 24,591 |
| Maturities of investments | 86,873 | 57,250 |
| Net cash provided by (used in) investing activities | 47,371 | 31,093 |
| Proceeds from exercise of stock options | 138 | 138 |
| Proceeds from purchase of espp shares | -233 | -134 |
| Payments to taxing authorities related to net-settlement of vested restricted stock units | 143 | 39 |
| Payments on finance leases | 98 | 66 |
| Net cash provided by financing activities | 130 | 167 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -14,524 | -11,564 |
| Cash and cash equivalents at beginning of period | 40,493 | - |
| Cash and cash equivalents at end of period | 25,969 | - |
Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc. (ARTV)